Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;39(1):21-4.
doi: 10.18773/austprescr.2016.008. Epub 2016 Feb 1.

Prescribing for patients on dialysis

Brendan Smyth  1 , Ceridwen Jones  1 , John Saunders  1
Affiliations
Review

Prescribing for patients on dialysis

Brendan Smyth et al. Aust Prescr. 2016 Feb.

Abstract

The pharmacokinetics of a drug may be altered in patients with renal impairment who require dialysis. Some drugs are contraindicated. The drug's clearance and therapeutic index determine if a dose adjustment is needed. A lower dose or less frequent dosing may be required. Consult a reference source or the patient's nephrologist before prescribing. Start at a low dose and increase gradually. If possible give once-daily drugs after dialysis.

Keywords: haemodialysis; kidney; pharmacokinetics; renal disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: none declared

Comment in

  • Metformin and patients on dialysis.
    Richards S. Richards S. Aust Prescr. 2016 Jun;39(3):74-5. doi: 10.18773/austprescr.2016.041. Epub 2016 Jun 1. Aust Prescr. 2016. PMID: 27345523 Free PMC article. No abstract available.

References

    1. Clayton P, McDonald S, Hurst K, editors. ANZDATA Registry Annual Report 2013. Adelaide: Australia and New Zealand Dialysis and Transplant Registry; 2013. www.anzdata.org.au/anzdata/AnzdataReport/36thReport/ANZDATA_36th_Annual%... [cited 2016 Jan 4]
    1. Manley HJ, Drayer DK, Muther RS. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrol 2003;4:10. 10.1186/1471-2369-4-10 - DOI - PMC - PubMed
    1. Weir MR, Fink JC. Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens 2014;23:306-13. 10.1097/01.mnh.0000444912.40418.45 - DOI - PubMed
    1. Faull R, Lee L. Prescribing in renal disease. Aust Prescr 2007;30:17-20.
    1. Meijers BK, Bammens B, Verbeke K, Evenepoel P. A review of albumin binding in CKD. Am J Kidney Dis 2008;51:839-50. 10.1053/j.ajkd.2007.12.035 - DOI - PubMed

LinkOut - more resources